Medpace (MEDP)
(Delayed Data from NSDQ)
$319.56 USD
+5.34 (1.70%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.56 USD
+5.34 (1.70%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
5 Stocks to Buy on a Possible Second Rate Cut in September
by Nalak Das
As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.
Medpace Holdings, Inc. (MEDP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Medpace Holdings, Inc. (MEDP).
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 28.57% and 6.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Medpace (MEDP) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medpace (MEDP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Near-Term Outlook for Medical Services Industry Looks Bright
by Urmimala Biswas
The third-party medical services industry is expanding rapidly.
Ensign Group (ENSG) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TVTY vs. MEDP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TVTY vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 10.14% and 4.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Teladoc in 2019, After a Strong 2018?
by Zacks Equity Research
Teladoc (TDOC) should continue to gain from increasing demand for its services and global expansion.
Cigna Poised for Growth in 2019 on Express Scripts Buyout
by Zacks Equity Research
The purchase of Express Scripts by Cigna (CI) has diversified its business, which should fuel long-term growth.
MEDP or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MEDP vs. HQY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
5 Healthcare Bets to Stay in Investors Good Books Next Year
by Zacks Equity Research
Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.
Teladoc (TDOC) Surges 64% in a Year: Can the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) is poised to grow on accelerating demand for its telehealth services.
PRA Health Sciences (PRAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
PRA Health Sciences (PRAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioTelemetry (BEAT) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
MEDP vs. PRAH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MEDP vs. PRAH: Which Stock Is the Better Value Option?
BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
MEDP vs. PRAH: Which Stock Is the Better Value Option?
by Zacks Equity Research
MEDP vs. PRAH: Which Stock Is the Better Value Option?
Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 6.35% and 2.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Medpace Holdings (MEDP) in Q3 Earnings?
by Zacks Equity Research
Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.
Medpace (MEDP) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.